High and low doses of clarithromycin treatment are associated with different clinical efficacies and immunomodulatory properties in chronic rhinosinusitis

Journal of Laryngology and Otology

Volumn 128, Issue 3, 2014, Pages 236-241

  Fan, Y ^a,b   Xu, R ^a   Hong, H ^b   Luo, Q ^b   Xia, W ^b   Ding, M ^a   Shi, J ^a   Lv, M ^b   Li, H ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Clarithromycin; IL 5; IL 8; Quality Of Life; Rhinitis; Treatment

Indexed keywords

CLARITHROMYCIN; INTERLEUKIN 5; INTERLEUKIN 8; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; ASTHMA; CHRONIC RHINOSINUSITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DRUG EFFICACY; DRUG MEGADOSE; ENDOSCOPY; FEMALE; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MALE; NOSE OBSTRUCTION; NOSE SECRETION; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; SHORT COURSE THERAPY; SINONASAL OUTCOME TEST 20; SMOKING; SYMPTOM ASSESSMENT; TREATMENT DURATION; VISUAL ANALOG SCALE; CHRONIC DISEASE; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DOSE RESPONSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CHRONIC DISEASE; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-5; INTERLEUKIN-8; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RHINITIS; SINUSITIS; TREATMENT OUTCOME;

EID: 84922060127     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215114000279     Document Type: Article

References (21)

1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012;50:1-12
2. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A et al. Chronic rhinosinusitis in Europe-an underestimated disease. A GA2LEN study. Allergy 2011;66:1216-23
3. Cervin A, Wallwork B. Anti-inflammatory effects of macrolide antibiotics in the treatment of chronic rhinosinusitis. Otolaryngol Clin North Am 2005;38:1339-50
4. Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope 2006;116:189-93
5. Cervin A, Wallwork B, Mackay-Sim A, Coman WB, Greiff L. Effects of long-term clarithromycin treatment on lavagefluid markers of inflammation in chronic rhinosinusitis. Clin Physiol Funct Imaging 2009;29:136-42
6. Luo Q, Chen F, Liu W, Li Z, Xu R, Fan Y et al. Evaluation of long-term clarithromycin treatment in adult Chinese patients with chronic rhinosinusitis without nasal polyps. ORL J Otorhinolaryngol Relat Spec 2011;73:206-11
7. Peuchant O, Ménard A, Renaudin H, Morozumi M, Ubukata K, Bébéar CM et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009;64:52-8
8. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008;52:348-50
9. Xin D, Mi Z, Han X, Qin L, Li J, Wei T et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009;53:2158-9
10. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother 2009;53:2160-2
11. Videler WJ, Badia L, Harvey RJ, Gane S, Georgalas C, van der Meulen FW et al. Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized controlled trial. Allergy 2011;66:1457-68
12. Zeng M, Long XB, Cui YH, Liu Z. Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults. Am J Rhinol Allergy 2011;25:203-7
13. Suzuki H, Ikeda K, Honma R, Gotoh S, Oshima T, Furukawa M et al. Prognostic factors of chronic rhinosinusitis under longterm low-dose macrolide therapy. ORL J Otorhinolaryngol Relat Spec 2000;62:121-7
14. Tamaoki J, Nakata J, Tagaya E, Konno K. Effects of roxithromycin and erythromycin on interleukin 8-induced neutrophil recruitment and goblet cell secretion in guinea pig tracheas. Antimicrob Agents Chemother 1996;40:1726-8
15. Cervin A, Wallwork B. Macrolide therapy of chronic rhinosinusitis. Rhinology 2007;45:259-67
16. Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med 1997;182:115-24
17. Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000;14:143-8
18. Hrvacić B, Bosnjak B, Bosnar M, Ferencić Z, Glojnarić I, Eraković Haber V. Clarithromycin suppresses airway hyperresponsiveness and inflammation in mouse models of asthma. Eur J Pharmacol 2009;616:236-43
19. Lin SJ, Lee WJ, Liang YW, Yan DC, Cheng PJ, Kuo ML. Azithromycin inhibits IL-5 production of T helper type 2 cells from asthmatic children. Int Arch Allergy Immunol 2011;156: 179-86
20. Park HH, Park IH, Cho JS, Lee YM, Lee HM. The effect of macrolides on myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts. Am J Rhinol Allergy 2010;24:348-53
21. Peric A, Vojvodic D, Baletic N, Peric A, Miljanovic O. Influence of allergy on the immunomodulatory and clinical effects of long-term low-dose macrolide treatment of nasal polyposis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010;154:327-33